Marie Jaspard1, Sylvain Juchet2, Béatrice Serra3, Baweye Mayoum4, Issa Malam Kanta5, Mohamed Seto Camara6, Placide Mbala7, Richard Kojan8, Denis Malvy9. 1. University of Bordeaux, National Institute for Health and Medical Research (Inserm), Research Institute for Sustainable Development (IRD), Bordeaux Population Health Center, UMR 1219, Bordeaux, France; The Alliance for International Medical Action, Dakar, Senegal. Electronic address: marie.jaspard@coral.alima.ngo. 2. University of Bordeaux, National Institute for Health and Medical Research (Inserm), Research Institute for Sustainable Development (IRD), Bordeaux Population Health Center, UMR 1219, Bordeaux, France; The Alliance for International Medical Action, Dakar, Senegal. Electronic address: sylvain.jucher@coral.alima.ngo. 3. University of Bordeaux, National Institute for Health and Medical Research (Inserm), Research Institute for Sustainable Development (IRD), Bordeaux Population Health Center, UMR 1219, Bordeaux, France; The Alliance for International Medical Action, Dakar, Senegal. Electronic address: beatrice.serra@coral.alima.ngo. 4. The Alliance for International Medical Action, Dakar, Senegal. Electronic address: baweye.mayoum@alima.ngo. 5. The Alliance for International Medical Action, Dakar, Senegal. Electronic address: issa.kanta@alima.ngo. 6. The Alliance for International Medical Action, Dakar, Senegal. Electronic address: setocamara@gmail.com. 7. Institut National de la Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo. Electronic address: mbalaplacide@gmail.com. 8. The Alliance for International Medical Action, Dakar, Senegal. Electronic address: richard.kojan@alima.ngo. 9. University of Bordeaux, National Institute for Health and Medical Research (Inserm), Research Institute for Sustainable Development (IRD), Bordeaux Population Health Center, UMR 1219, Bordeaux, France; Department for infections and tropical diseases, University Hospital of Bordeaux, Bordeaux, France. Electronic address: denis.malvy@chu-bordeaux.fr.
Abstract
INTRODUCTION: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts. DESIGN: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. RESULTS: Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1-2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. CONCLUSION: Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted.
INTRODUCTION: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts. DESIGN: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. RESULTS: Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1-2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. CONCLUSION: Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted.
Authors: Ian Crozier; Kyla A Britson; Daniel N Wolfe; John D Klena; Lisa E Hensley; John S Lee; Larry A Wolfraim; Kimberly L Taylor; Elizabeth S Higgs; Joel M Montgomery; Karen A Martins Journal: Vaccines (Basel) Date: 2022-07-29